TuHURA Biosciences, Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 13, 2023 and accepted by EDGAR at Nov 13, 2023, 21:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-07-01 to 2023-09-30 | $1.9m | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$3.0m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | −$1.83 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2023-07-01 to 2023-09-30 | −$1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $216.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $783.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $1.5m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $3.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $3.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | −$2.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-062915. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.